Pfizer intends to do a phase 3 study of tofacitinib 5 mg bid (vs PBO) in adults with active ankylosing spondylitis ~ 240 pts in a multinational study. Previously a 16 week, phase 2 trial showed an 82% ASAS20 response in AS pts. https://t.co/u1I0Tpdtl6